Skip to main content
SpringerLink
Log in

Measuring Quality of Life in Patients with Depression or Anxiety

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

One-fifth of all disability is caused by psychiatric morbidity, with depression and anxiety the most common conditions. Despite this, and the wide range of pharmaceutical treatments available, few quality-of-life studies have been conducted with depressed or anxious patients. Most studies focus on symptoms and adverse effects, rather than on the impact of these on the patient. Where health status is assessed, inappropriate generic measures have been used.

Recently, a depression-specific measure of quality of life, the Quality of Life in Depression Scale, has been developed and is starting to be used in clinical trials. No equivalent measure for anxiety is available. Given the range and rapid increase in the number of treatments available for depression and anxiety, and issues of compliance and individual response to treatment, much more attention must be given to quality of life in these conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987

    Google Scholar 

  2. Rickels K. Antianxiety therapy: potential value of long-term treatment. J Clin Psychiatry 1987; 48 Suppl.: 7–11

    PubMed  Google Scholar 

  3. Leckman JF, Weissman MM, Merikangas KR, et al. Panic disorder and major depression: increased risk of depression, alcoholism, panic and phobic disorders of depressed probands in families of depressed probands with panic disorder. Arch Gen Psychiatry 1983; 40: 1055–160

    Article  PubMed  CAS  Google Scholar 

  4. Robinson DS, Kayser A, Corcella J, et al. Panic attacks in out-patients with depression: response to antidepressant treatment. Psychopharmacol Bull 1985; 21: 562–7

    PubMed  CAS  Google Scholar 

  5. Clancy J, Noyes Jr R, Hoenk PR, et al. Secondary depression and anxiety neurosis. J Nerv Ment Dis 1978; 166: 846–50

    Article  PubMed  CAS  Google Scholar 

  6. Breier A, Charney DS, Heninger GR. Major depression in panic disorder. Arch Gen Psychiatry 1984; 41: 1125–39

    Article  Google Scholar 

  7. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63–70

    Article  PubMed  CAS  Google Scholar 

  8. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71

    Article  PubMed  CAS  Google Scholar 

  9. Carroll BJ, Feinberg M, Smouse PE, et al. The Carroll rating scale for depression: I. Development, reliability and validation. Br J Psychiatry 1981; 138: 194–200

    Article  PubMed  CAS  Google Scholar 

  10. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Measurement 1977; 1: 385–401

    Article  Google Scholar 

  11. Weissman MM, Sholomskas D, Pottenger M, et al. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 1977; 106: 203–14

    PubMed  CAS  Google Scholar 

  12. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62

    Article  PubMed  CAS  Google Scholar 

  13. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 276–96

    Article  Google Scholar 

  14. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9

    Article  PubMed  CAS  Google Scholar 

  15. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–5

    Article  PubMed  CAS  Google Scholar 

  16. Snaith RP, Baugh SJ, Clayden AD, et al. The Clinical Anxiety Scale: a modification of the Hamilton Anxiety Scale. Br J Psychiatry 1982; 141: 518–23

    Article  PubMed  CAS  Google Scholar 

  17. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893–7

    Article  PubMed  CAS  Google Scholar 

  18. Derogatis LR. SCL-90-R: administration, scoring and procedures manual II. Towson (MD): Clinical Psychometrics Research, 1983

    Google Scholar 

  19. Goldberg D. The detection of psychiatric illness by questionnaire. London: Oxford University Press, 1972

    Google Scholar 

  20. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–70

    Article  PubMed  CAS  Google Scholar 

  21. Rudorfer MV, Potter WZ. Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the ‘newer’ versus the ‘older’ drugs. Drugs 1989; 37: 713–38

    Article  PubMed  CAS  Google Scholar 

  22. Patrick DL, Erickson P. Health status and health policy. New York: Oxford University Press, 1993

    Google Scholar 

  23. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473–83

    Article  PubMed  Google Scholar 

  24. McKenna SP, Hunt SM, Tennant A. Psychological well-being in depressed patients. Int J Methods Psychiatr Res 1993; 3: 245–51

    Google Scholar 

  25. Hunt SM, McKenna SP. A British adaptation of the General Well-Being Index: a new tool for clinical research. Br J Med Econ 1992; 2: 49–60

    Google Scholar 

  26. Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy 1992; 22: 307–19

    Article  PubMed  CAS  Google Scholar 

  27. McKenna SP, Hunt SM. A new measure of quality of life in depression: testing the reliability and construct validity of the QLDS. Health Policy 1992; 22: 321–30

    Article  PubMed  CAS  Google Scholar 

  28. Hunt SM, Kovachich P, McKenna SP. Genital herpes and quality of life. Br J Sex Med 1993; 20: 12–5

    Google Scholar 

  29. McKenna SP, Doward L.C. Quality-of-life assessment of adults with growth hormone deficiency: implications for drug therapy. PharmacoEconomics 1994; 6 (5): 434–41

    Article  PubMed  CAS  Google Scholar 

  30. Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. New York: Oxford University Press, 1989: 113–20

    Google Scholar 

  31. Prusoff B, Klerman G, Paykel E. Concordance between clinical assessments and patients’ self report in depression. Arch Gen Psychiatry 1972; 26: 546–52

    Article  PubMed  CAS  Google Scholar 

  32. Berzon R, Hays RD, Shumaker SA. International use, application and performance of health-related quality of life instruments. Qual Life Res 1993; 2: 367–8

    Article  PubMed  CAS  Google Scholar 

  33. Rost K, Smith GR, Burnman MA, et al. Measuring the outcomes of care for mental health problems: the case of depressive disorders. Med Care 1992; 30 (5 Suppl.): MS266–73

    Google Scholar 

  34. Weiner E, Stewart B. Assessing individuals. Boston: Little Brown, 1984

    Google Scholar 

  35. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. New York: Oxford University Press, 1987: 12–35

    Google Scholar 

  36. Cortina JM. What is coefficient alpha? An examination of theory and applications. J Appl Psychol 1993; 78: 98–104

    Article  Google Scholar 

  37. Tuynman-Qua H, de Jonghe F, McKenna SP, et al. Quality of Life in Depression Rating Scale (QLDS). Houten (The Netherlands): Ibero Publications, 1992

    Google Scholar 

  38. Grégoire J, de Leval N, Mesters P, et al. Validation of the Quality of Life in Depression Scale in a population of adult depressive patients aged 60 and above. Qual Life Res 1994; 3: 13–9

    Article  PubMed  Google Scholar 

  39. Stoker MJ, Dunbar GC, Beaumont G. The SmithKline Beecham ‘quality of life’ scale: a validation and reliability study in patient with affective disorder. Qual Life Res 1992; 1: 385–95

    Article  PubMed  CAS  Google Scholar 

  40. Joyce CRB. Report from the European Standard for Clinical Trials (ESCT) meeting in Strasbourg 23–24 May 1991, on issues of concern in the standardization and harmonization of drug trials in Europe: health-related quality of life session. Qual Life Newsletter 1992; 3: 10

    Google Scholar 

  41. Kelly GA. The psychology of personal constructs. New York: WW Norton, 1955

    Google Scholar 

  42. Bergner M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805

    Article  PubMed  CAS  Google Scholar 

  43. Revicki DA, Turner R, Brown R, et al. Reliability and validity of health-related quality of life battery for evaluating out-patient antidepressant treatment. Qual Life Res 1992; 1: 257–66

    Article  PubMed  CAS  Google Scholar 

  44. Stewart AL, Ware JE. Measuring functioning and well-being: the Medical Outcomes Study approach. Durham (NC): Duke University Press, 1992

    Google Scholar 

  45. Omvik P, Thaulow E, Herland OB, et al. Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicenter study. J Hypertens 1993; 11: 103–13

    Article  PubMed  CAS  Google Scholar 

  46. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the medical outcomes study. JAMA 1989; 262: 914–9

    Article  PubMed  CAS  Google Scholar 

  47. Broadhead WE, Blazer DG, George LK, et al. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990; 264: 2524–8

    Article  PubMed  CAS  Google Scholar 

  48. Campbell A, Converse PE, Rogers WL. The quality of American life. New York: Russell Sage Foundation, 1976

    Google Scholar 

  49. Endicott J, Nee J, Harrison W, et al. Quality of life enjoyment and satisfaction questionnaire: a new measure. Department of Psychiatry, Columbia University and New York State Psychiatric Institute. Psychopharmacol Bull 1993; 29: 321–6

    PubMed  CAS  Google Scholar 

  50. Salamon MJ, Conte VA. The life satisfaction in the elderly scale. Odessa (FL): Psychological Assessment Resources, 1984

    Google Scholar 

  51. Schooler N, Hogarty G, Weissman MM. Social Adjustment Scale II (SASII). In: Hargreaves WA, Attkisson CC, Sorensen JE, editors. Resource materials for community health program evaluators. Publ. No. (ADM) 79–328. Washington, DC: US Department of Health, Education and Welfare, 1979: 290–330

    Google Scholar 

  52. Gershon S. The conduct of clinical trials in the impaired elderly. Psychopharmacol Bull 1981; 17: 108–16

    PubMed  CAS  Google Scholar 

  53. Hill S, Harries U. Assessing the outcome of health care for older people in community settings: should we use the SF-36? Outcomes Briefing 1994 Aug; 4: 26–7

    Google Scholar 

  54. Brazier J, Harper R, Jones N, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMl 1992; 305: 160–4

    Article  CAS  Google Scholar 

  55. Ienkinson C, Coutler A, Wright L. Short form 36 (SF 36) health survey questionnaire: normative data for adults of working age. BMJ 1993; 306: 1437–40

    Article  Google Scholar 

  56. Mesters P, Cosyns P, Dejaiffe G, et al. Assessment of quality of life in the treatment of major depressive disorder with fluoxetine, 20 mg, in ambulatory patients aged over 60 years. Int Clin Psychopharmacol 1993; 8: 337–40

    Article  PubMed  CAS  Google Scholar 

  57. Hunt SM, McEwen J, McKenna SP. Measuring health status. London: Croom Helm, 1986

    Google Scholar 

  58. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 1993; 150: 600–7

    PubMed  CAS  Google Scholar 

  59. Stewart AL, Hays RD, Ware JE. The MOS Short-Form General Health Survey: reliability and validity in a patient population. Med Care 1988; 26: 724–35

    Article  PubMed  CAS  Google Scholar 

  60. Keller MB, Lavori PW, Friedman B, et al. The longitudinal interval follow-up evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry 1987; 44: 540–8

    Article  PubMed  CAS  Google Scholar 

  61. Markowitz JS, Weissman MM, Ouellette R, et al. Quality of life in panic disorder. Arch Gen Psychiatry 1989; 46: 984–92

    Article  PubMed  CAS  Google Scholar 

  62. Fifer SK, Mathias SD, Patrick DL, et al. Untreated anxiety among adult primary care patients in a health maintenance organization. Arch Gen Psychiatry 1994; 51: 740–50

    Article  PubMed  CAS  Google Scholar 

  63. Lonnqvist J, Sintonen H, Syvalahti E, et al. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and tluoxetine. Acta Psychiatr Scand 1994; 89 (6): 363–9

    Article  PubMed  CAS  Google Scholar 

  64. Silverstone T. Moclobemide placebo-controlled trials. Int Clin Psychopharmacol 1993; 7 (3–4): 133–6

    Article  PubMed  CAS  Google Scholar 

  65. Hall J. Fluoxetine: efficacy against placebo and by dose — an overview. Br J Psychiatry 1988; 153 (3 Suppl.): 59–63

    Google Scholar 

  66. Sintonen H, Pekurinen M. A generic 15 dimensional measure of health-related quality of life (15D). J Social Med 1989; 26: 85–96

    Google Scholar 

  67. Evans OW, McCartney CF, Haggerty JJ, et al. Treatment of depression in cancer patients is associated with better life adaptation: a pilot study. Psychosom Med 1988; 50 (1): 72–6

    Google Scholar 

  68. Derogatis LR. The psychosocial adjustment to illness scale (PAIS). J Psychosom Res 1986; 30 (1): 77–91

    Article  PubMed  CAS  Google Scholar 

  69. Katon W, Sullivan M. Depression and chronic medical illness. J Clin Psychiatry 1990; 51 (6 Suppl.): 3–14

    PubMed  Google Scholar 

  70. Schulberg H, Coulehan J, Block M, et al. Strategies for evaluating treatments for major depression in primary care patients. Gen Hosp Psychiatry 1991; 13: 9–18

    Article  PubMed  CAS  Google Scholar 

  71. Thompson C, Thompson CM. The prescribing of antidepressants in general practice: I. A critical review. Human Psychopharmacol 1989; 4: 190

    Google Scholar 

  72. Paykel ES, Freeling P, Hollyman JA. Are tricyclic antidepressants useful for mild depression? A placebo controlled trial. Pharmacopsychiatry 1988; 21: 15–8

    Article  PubMed  CAS  Google Scholar 

  73. Katon W, von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30: 67–76

    Article  PubMed  CAS  Google Scholar 

  74. Johnson DAW. Treatment of depression in general practice. BMJ 1973; 2: 18–20

    Article  PubMed  CAS  Google Scholar 

  75. Thompson J, Rankin H, Ashcroft CW, et al. The treatment of depression in general practice. Psychol Med 1982; 12: 741–51

    Article  Google Scholar 

  76. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217–22

    Article  PubMed  CAS  Google Scholar 

  77. Klerman GL, Dimascio A, Weissman A, et al. Treatment of depression by drugs and psychotherapy. Am J Psychiatry 1974; 131: 186–91

    PubMed  CAS  Google Scholar 

  78. Montgomery SA, Dunbar GC. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int J Psychopharmacol 1993; 8: 189–95

    Article  CAS  Google Scholar 

  79. Lader M. Dependence on benzodiazepines. J Clin Psychiatry 1983; 44: 121–7

    PubMed  CAS  Google Scholar 

  80. Winokur A, Rickels K, Greenblatt DJ. Withdrawal reaction from long-term, low dosage administration of diazepam. Arch Gen Psychiatry 1980; 37: 101–5

    Article  PubMed  CAS  Google Scholar 

  81. Rickels K, Csanalosi I, Greisman P, et al. A controlled clinical trial of alprazolam for the treatment of anxiety. Am J Psychiatry 1983; 140: 82–5

    PubMed  CAS  Google Scholar 

  82. Jonas JM, Cohon MS. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. J Clin Psychiatry 1993; 54 Suppl.: 25–48

    PubMed  Google Scholar 

  83. Goa KL, Ward A. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32: 114–29

    Article  PubMed  CAS  Google Scholar 

  84. Rickels K, Cohen D, Csanalosi I, et al. Alprazolam and imipramine in depressed outpatients: a controlled study. Curr Ther Res 1982; 32 (6): 157–64

    Google Scholar 

  85. Cole JO, Orzack MH, Beake B, et al. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 1982; 43 (12 Sect. 2): 69–74

    PubMed  CAS  Google Scholar 

  86. Murphy SM, Owen RT, Tyrer PJ. Withdrawal symptoms after six weeks treatment with diazepam [abstract]. Lancet 1984; 2: 1389

    Article  PubMed  CAS  Google Scholar 

  87. Feighner JP. A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients. In: Ashcroft GW, editor. Depression — a once in a lifetime event? Oxford: Clinical Neuroscience Publishers, 1991

    Google Scholar 

  88. Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992; 267: 1478–83

    Article  PubMed  CAS  Google Scholar 

  89. Kind P, Sorensen J. The costs of depression. Third international symposium: RIMAs in subtypes of depression: focus on moclobemide; 1992: Vienna. Int Clin Psychopharmacol 1993; 7 (3–4): 191–5

    Article  PubMed  CAS  Google Scholar 

  90. Souêtre E, Lozet H, Cimarosti I. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res 1994; 38 (1 Suppl.): 151–60

    Article  PubMed  Google Scholar 

  91. Keller MB, Shapiro RW, Lavori PW, et al. Relapse in major depressive disorder: analysis with life table. Arch Gen Psychiatry 1982; 39: 911–5

    Article  PubMed  CAS  Google Scholar 

  92. Henry JA. Debits and credits in the management of depression. Br J Psychiatry 1993; 163 Suppl. 20: 33–9

    Google Scholar 

  93. Murphy GRE. The physician’s responsibility for suicide: 1. An error of commission; and 2. Errors of omission. Ann Intern Med 1975; 82: 301–9

    PubMed  CAS  Google Scholar 

  94. Katon W, Roy-Byrne PP. Antidepressants in the medically ill: diagnosis and treatment in primary care. Clin Chem 1988; 34 (5): 829–36

    PubMed  CAS  Google Scholar 

  95. Prescott LF, Highley MS. Drugs prescribed for self-poisoners. BMJ 1985; 290: 1633–6

    Article  PubMed  CAS  Google Scholar 

  96. Weissman MM. The epidemiology of suicide attempts, 1960- 1971. Arch Gen Psychiatry 1974; 30: 737–46

    Article  PubMed  CAS  Google Scholar 

  97. Gerner R, Estabrook W, Steuer J, et al. Treatment of geriatric depression with trazodone, imipramine and placebo: a double-blind study. J Clin Psychiatry 1980; 41: 216–20

    PubMed  CAS  Google Scholar 

  98. Henry JA. The safety of antidepressants. Br J Psychiatry 1992; 160: 439–41

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Galen Research, Manchester, England

    Diane Whalley

  2. Care Outcomes Group, Rheumatology and Rehabilitation Research Unit, The University of Leeds, Leeds, England

    Stephen P. McKenna

Authors
  1. Diane Whalley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen P. McKenna
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Whalley, D., McKenna, S.P. Measuring Quality of Life in Patients with Depression or Anxiety. Pharmacoeconomics 8, 305–315 (1995). https://doi.org/10.2165/00019053-199508040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199508040-00005

Keywords

Search

Navigation